Australia's most trusted
source of pharma news
Posted 12 June 2025 PM
Danish pharma giant, Novo Nordisk, is using a new partnership with the mobile healthcare delivery provider Heart of Australia (HoA) to bring more clinical trial opportunities to regional, rural and remote communities in Queensland.
Novo says that, although Australia's clinical trial sector contributed $1.6 billion to the national economy in 2022, regional, rural and remote communities remain underrepresented in medical research. It is aiming to boost trial participation opportunities for these communities via its alliance with the Heart of Australia Research Institute (HARI), an initiative launched last year by HoA.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.